Utilizing CMA inhibitors to treat tumor-bearing mice exhibited heightened immune cell infiltration, particularly of effector CD8+ T cells, and a simultaneous augmentation in responsiveness to immune checkpoint blockade (ICB). This evidence concerns the gene CD8A and neoplasm.